title: Rhesus macaque model for ovarian cancer chemoprevention.
abstract: OBJECTIVE
  The objective of the study reported here was to explore whether a nonhuman primate model could be developed for chemoprevention of ovarian cancer.
  
  
  METHODS
  An initial feasibility trial was done with three monkeys to determine tolerance for these drugs and for acquisition of surgical ovarian biopsy specimens. In the study, 19 female adult Macacca mulatta (rhesus macaques) were given fenretinide (4HPR) oral contraceptive (OCP), the combination of 4HPR+OCP, or no medication for three months. Laparotomy was performed before and after drug administration, and ovarian biopsy specimens were obtained to evaluate the potential for this animal as a model for ovarian cancer chemoprevention, as well as evaluating fluorescence spectroscopy and other potential biomarkers for ovarian cancer prevention studies.
  
  
  RESULTS
  The monkeys tolerated the drugs, surgeries, and acquisition of multiple ovarian biopsy specimens with resultant minimal morbidity. On initial data analysis, fluorescence spectroscopy was the marker that appeared the most promising.
  
  
  CONCLUSIONS
  On the basis of results of this study, this model merits further investigation. The rhesus monkey is an excellent candidate for a nonhuman primate model for ovarian cancer chemoprevention.
authors.affiliation: Department of Veterinary Sciences Science Park, The University of Texas M. D. Anderson Cancer Center, Houston 7030, USA.
authors.forename: M
authors.initials: M
authors.lastname: Brewer
authors.forename: W
authors.initials: W
authors.lastname: Baze
authors.forename: L
authors.initials: L
authors.lastname: Hill
authors.forename: U
authors.initials: U
authors.lastname: Utzinger
authors.forename: J T
authors.initials: JT
authors.lastname: Wharton
authors.forename: M
authors.initials: M
authors.lastname: Follen
authors.forename: F
authors.initials: F
authors.lastname: Khan-Dawood
authors.forename: W
authors.initials: W
authors.lastname: Satterfield
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000032:analysis; D001706:Biopsy; D003277:Contraceptives, Oral, Combined / Q000494:pharmacology; D004195:Disease Models, Animal; D004338:Drug Combinations; D005260:Female; D017313:Fenretinide / Q000494:pharmacology; D006801:Humans; D008253:Macaca mulatta; D008656:Mestranol / Q000494:pharmacology; D009640:Norethindrone / Q000494:pharmacology; D010051:Ovarian Neoplasms / Q000517:prevention & control*; D010053:Ovary / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism; D013050:Spectrometry, Fluorescence
chemical_list: D016588:Anticarcinogenic Agents; D014408:Biomarkers, Tumor; D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D017313:Fenretinide; C014715:Norinyl; D008656:Mestranol; D009640:Norethindrone